What is HC Wainwright's Forecast for SNDX Q1 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. White anticipates that the company will post earnings of ($1.00) per share for the quarter. HC Wainwright has a "Buy" rating and a $51.00 price objective on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals' Q2 2025 earnings at ($0.98) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.92) EPS and FY2027 earnings at ($1.44) EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to analysts' expectations of $86.32 million.

Several other equities analysts have also recently weighed in on the company. Citigroup reduced their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. boosted their price target on shares of Syndax Pharmaceuticals from $35.00 to $39.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Scotiabank lowered their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. Finally, StockNews.com cut Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, November 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $36.00.

Remove Ads

Syndax Pharmaceuticals Trading Down 6.1 %

Shares of NASDAQ:SNDX traded down $0.87 during mid-day trading on Wednesday, reaching $13.42. The company had a trading volume of 3,422,059 shares, compared to its average volume of 2,354,926. Syndax Pharmaceuticals has a one year low of $12.06 and a one year high of $25.16. The company's 50-day moving average price is $14.33 and its 200-day moving average price is $16.60. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -3.70 and a beta of 0.92.

Insider Activity at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 13,288 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the transaction, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now owns 85,095 shares of the company's stock, valued at $1,318,972.50. The trade was a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,683 shares of company stock valued at $336,087. Corporate insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Simplify Asset Management Inc. raised its stake in shares of Syndax Pharmaceuticals by 62.5% during the third quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company's stock valued at $2,352,000 after acquiring an additional 46,992 shares during the last quarter. Franklin Resources Inc. increased its holdings in Syndax Pharmaceuticals by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock valued at $34,948,000 after purchasing an additional 208,043 shares during the period. State Street Corp raised its position in Syndax Pharmaceuticals by 4.1% during the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company's stock valued at $72,588,000 after purchasing an additional 148,491 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Syndax Pharmaceuticals by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company's stock worth $13,397,000 after buying an additional 41,458 shares during the period. Finally, Barclays PLC grew its position in shares of Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company's stock worth $3,612,000 after buying an additional 110,535 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).